<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618774</url>
  </required_header>
  <id_info>
    <org_study_id>1235.16</org_study_id>
    <nct_id>NCT00618774</nct_id>
  </id_info>
  <brief_title>An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination</brief_title>
  <official_title>An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To assess the long term safety and efficacy of telmisartan plus amlodipine FDC in patients
      with essential hypertension who failed to control their BP with either monotherapy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experienced Adverse Events</measure>
    <time_frame>52 weeks</time_frame>
    <description>An adverse event is defined as any untoward medical occurrence</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG</measure>
    <time_frame>First administration of study treatment to 24 hours post last dosing of study treatment.</time_frame>
    <description>Clinically relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Seated Diastolic Blood Pressure at Week 8</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Seated Systolic Blood Pressure at Week 8</measure>
    <time_frame>Baseline and week 8</time_frame>
    <description>mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated DBP Control Rate at Trough After 8 Weeks</measure>
    <time_frame>week 8</time_frame>
    <description>Percentage of patients whose DBP &lt;90 mmHg after 8 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated SBP Control Rate at Trough After 8 Weeks</measure>
    <time_frame>Week 8</time_frame>
    <description>Percentage of patients whose SBP &lt;140 mmHg after 8 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Seated Diastolic Blood Pressure</measure>
    <time_frame>Baseline and week 20 / week 48</time_frame>
    <description>Mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Seated Systolic Blood Pressure</measure>
    <time_frame>Baseline and week 20 / week 48</time_frame>
    <description>mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated DBP Control Rate at Trough After 6 and 12 Months</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Percentage of patients whose DBP &lt;90 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated SBP Control Rate at Trough After 6 and 12 Months</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Percentage of patients whose SBP &lt;140 mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated DBP Response Rate at Trough</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Percentage of patients whose DBP &lt;90 mmHg or decreased from pseudo-baseline by &gt;=10 mmHg at 6 months and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated SBP Response Rate at Trough</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Percentage of patients whose SBP &lt;140 mmHg or decreased deom pseudo-baseline by &gt;=20 mmHg after 6 and 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seated Blood Pressure Normalisation at Trough</measure>
    <time_frame>6 months and 12 months</time_frame>
    <description>Percentage of patients when classifying their blood pressure measurements into the following classes at 6 and 12 months:
Optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg
Normal: SBP &gt;=120 mmHg or DBP &gt;=80 mmHg and SBP &lt;130 mmHg or DBP &lt;85 mmHg
High normal: SBP &gt;=130 mmHg or DBP &gt;=85 mmHg and SBP &lt;140 mmHg or DBP &lt;90 mmHg
No: SBP &gt;=140 mmHg or DBP &gt;=90 mmHg</description>
  </secondary_outcome>
  <enrollment type="Actual">259</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan40/amlodipine5</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telmisartan80/amlodipine5</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with essential hypertension

          2. Outpatient

        Exclusion Criteria:

          -  Patients whose SBP &gt;=180 mmHg or DBP &gt;=110 mmHg at the end of treatment visit of the
             double-blind treatment period in the &quot;non-responder trials&quot;

          -  Patients who have met any of the exclusion criteria defined in the &quot;non-responder
             trials&quot;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1235.16.004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chofu, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.16.006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nishi-ku, Hiroshima, Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.16.005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.16.007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.16.003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjuku-ku, Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.16.001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Shinjyuku-ku,Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1235.16.002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Suita, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <results_first_submitted>December 28, 2009</results_first_submitted>
  <results_first_submitted_qc>February 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 3, 2010</results_first_posted>
  <last_update_submitted>June 17, 2014</last_update_submitted>
  <last_update_submitted_qc>June 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
        </group>
        <group group_id="P2">
          <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="211"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
        </group>
        <group group_id="B2">
          <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="211"/>
            <count group_id="B2" value="48"/>
            <count group_id="B3" value="259"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.8" spread="9"/>
                    <measurement group_id="B2" value="51.1" spread="8"/>
                    <measurement group_id="B3" value="55.8" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Experienced Adverse Events</title>
        <description>An adverse event is defined as any untoward medical occurrence</description>
        <time_frame>52 weeks</time_frame>
        <population>Treated set for safety, which was the analysis set including all the patients who had valid measurements after drug administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Experienced Adverse Events</title>
          <description>An adverse event is defined as any untoward medical occurrence</description>
          <population>Treated set for safety, which was the analysis set including all the patients who had valid measurements after drug administration.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.3"/>
                    <measurement group_id="O2" value="77.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Seated Diastolic Blood Pressure at Week 8</title>
        <description>mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure</description>
        <time_frame>Baseline and week 8</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Diastolic Blood Pressure at Week 8</title>
          <description>mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.81" spread="6.65"/>
                    <measurement group_id="O2" value="15.75" spread="6.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Seated Systolic Blood Pressure at Week 8</title>
        <description>mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure</description>
        <time_frame>Baseline and week 8</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Systolic Blood Pressure at Week 8</title>
          <description>mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.89" spread="12.2"/>
                    <measurement group_id="O2" value="26.44" spread="11.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated DBP Control Rate at Trough After 8 Weeks</title>
        <description>Percentage of patients whose DBP &lt;90 mmHg after 8 weeks of treatment</description>
        <time_frame>week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Seated DBP Control Rate at Trough After 8 Weeks</title>
          <description>Percentage of patients whose DBP &lt;90 mmHg after 8 weeks of treatment</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.8"/>
                    <measurement group_id="O2" value="52.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated SBP Control Rate at Trough After 8 Weeks</title>
        <description>Percentage of patients whose SBP &lt;140 mmHg after 8 weeks of treatment</description>
        <time_frame>Week 8</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Seated SBP Control Rate at Trough After 8 Weeks</title>
          <description>Percentage of patients whose SBP &lt;140 mmHg after 8 weeks of treatment</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2"/>
                    <measurement group_id="O2" value="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Seated Diastolic Blood Pressure</title>
        <description>Mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure</description>
        <time_frame>Baseline and week 20 / week 48</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Diastolic Blood Pressure</title>
          <description>Mean reduction from pseud-baseline (after the washout) in seated diastolic blood pressure</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.67" spread="7.16"/>
                    <measurement group_id="O2" value="16.36" spread="5.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.39" spread="6.6"/>
                    <measurement group_id="O2" value="17.78" spread="7.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Seated Systolic Blood Pressure</title>
        <description>mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure</description>
        <time_frame>Baseline and week 20 / week 48</time_frame>
        <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Seated Systolic Blood Pressure</title>
          <description>mean reduction from pseud-baseline (after the washout) in seated systolic blood pressure</description>
          <population>Full analysis set for blood pressure measurements, which was the analysis set including all the patients who had valid measurements at the reference baseline and at one or more time-points after reference baseline.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.73" spread="12.55"/>
                    <measurement group_id="O2" value="27.18" spread="11.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.97" spread="11.75"/>
                    <measurement group_id="O2" value="28.11" spread="12.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated DBP Control Rate at Trough After 6 and 12 Months</title>
        <description>Percentage of patients whose DBP &lt;90 mmHg.</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Seated DBP Control Rate at Trough After 6 and 12 Months</title>
          <description>Percentage of patients whose DBP &lt;90 mmHg.</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.8"/>
                    <measurement group_id="O2" value="54.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.8"/>
                    <measurement group_id="O2" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated SBP Control Rate at Trough After 6 and 12 Months</title>
        <description>Percentage of patients whose SBP &lt;140 mmHg</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Seated SBP Control Rate at Trough After 6 and 12 Months</title>
          <description>Percentage of patients whose SBP &lt;140 mmHg</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7"/>
                    <measurement group_id="O2" value="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.2"/>
                    <measurement group_id="O2" value="89.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated DBP Response Rate at Trough</title>
        <description>Percentage of patients whose DBP &lt;90 mmHg or decreased from pseudo-baseline by &gt;=10 mmHg at 6 months and 12 months</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Seated DBP Response Rate at Trough</title>
          <description>Percentage of patients whose DBP &lt;90 mmHg or decreased from pseudo-baseline by &gt;=10 mmHg at 6 months and 12 months</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.1"/>
                    <measurement group_id="O2" value="85.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6"/>
                    <measurement group_id="O2" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated SBP Response Rate at Trough</title>
        <description>Percentage of patients whose SBP &lt;140 mmHg or decreased deom pseudo-baseline by &gt;=20 mmHg after 6 and 12 months</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Seated SBP Response Rate at Trough</title>
          <description>Percentage of patients whose SBP &lt;140 mmHg or decreased deom pseudo-baseline by &gt;=20 mmHg after 6 and 12 months</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6"/>
                    <measurement group_id="O2" value="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.6"/>
                    <measurement group_id="O2" value="93.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seated Blood Pressure Normalisation at Trough</title>
        <description>Percentage of patients when classifying their blood pressure measurements into the following classes at 6 and 12 months:
Optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg
Normal: SBP &gt;=120 mmHg or DBP &gt;=80 mmHg and SBP &lt;130 mmHg or DBP &lt;85 mmHg
High normal: SBP &gt;=130 mmHg or DBP &gt;=85 mmHg and SBP &lt;140 mmHg or DBP &lt;90 mmHg
No: SBP &gt;=140 mmHg or DBP &gt;=90 mmHg</description>
        <time_frame>6 months and 12 months</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Seated Blood Pressure Normalisation at Trough</title>
          <description>Percentage of patients when classifying their blood pressure measurements into the following classes at 6 and 12 months:
Optimal: SBP &lt;120 mmHg and DBP &lt;80 mmHg
Normal: SBP &gt;=120 mmHg or DBP &gt;=80 mmHg and SBP &lt;130 mmHg or DBP &lt;85 mmHg
High normal: SBP &gt;=130 mmHg or DBP &gt;=85 mmHg and SBP &lt;140 mmHg or DBP &lt;90 mmHg
No: SBP &gt;=140 mmHg or DBP &gt;=90 mmHg</description>
          <population>FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 20: Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                    <measurement group_id="O2" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3"/>
                    <measurement group_id="O2" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: High Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="45.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Optimal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4"/>
                    <measurement group_id="O2" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.2"/>
                    <measurement group_id="O2" value="18.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: High Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="39.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48: No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0"/>
                    <measurement group_id="O2" value="35.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG</title>
        <description>Clinically relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as adverse events.</description>
        <time_frame>First administration of study treatment to 24 hours post last dosing of study treatment.</time_frame>
        <population>Treated set</population>
        <group_list>
          <group group_id="O1">
            <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
          <group group_id="O2">
            <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
          </group>
        </group_list>
        <measure>
          <title>Clinically Relevant Abnormalities for Changes in Blood Pressure and Pulse Rate Due to Position Change, Seated Pulse Rate, Laboratory Parameters and ECG</title>
          <description>Clinically relevant abnormalities for changes in blood pressure and pulse rate due to position change, seated pulse rate, laboratory parameters and ECG. New abnormal findings or worsening of baseline conditions were reported as adverse events.</description>
          <population>Treated set</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="211"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Blood Pressure Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostatic specific antigen increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arrhythmia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atrial fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extrasystoles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ventricular extrasystoles</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthostatic hypotension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>While being treated with T20+A5, T40/A5, T80/A5, T40/A5+additional treatment, T80/A5+additional treatment and within 24 hours from the last dosing of any of them.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Telmisartan 40 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
        </group>
        <group group_id="E2">
          <title>Telmisartan 80 mg Plus Amlodipine 5 mg Fixed-dose Combination</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
              <event>
                <sub_title>Renal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="211"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="48"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

